Last update 21 Nov 2024

ELND-002

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Target
CD49d
Mechanism
CD49d antagonists(Integrin alpha-4 antagonists)
Therapeutic Areas
NeoplasmsImmune System DiseasesNervous System Diseases+ [2]
Active Indication-
Inactive Indication
Hematologic NeoplasmsMultiple sclerosis relapse
Originator Organization
Perrigo Co. PlcPerrigo Co. Plc
Active Organization-
Inactive Organization
Elan Corp. PlcElan Corp. PlcPerrigo Co. PlcPerrigo Co. PlcElan Corp.Elan Corp.
Drug Highest PhaseDiscontinuedPhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC93H104N18O24S6
InChIKeyLVISQNUEBNOMII-UHFFFAOYSA-N
CAS Registry873687-18-4

Related

2
Clinical Trials associated with ELND-002
NCT01318421 / TerminatedPhase 1
An Open-Label, Long-Term, Follow-Up Study of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
NCT01144351 / TerminatedPhase 1
A Phase 1b, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
100 Clinical Results associated with ELND-002
Login to view more data
100 Translational Medicine associated with ELND-002
Login to view more data
100 Patents (Medical) associated with ELND-002
Login to view more data
100 Deals associated with ELND-002
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple sclerosis relapsePhase 1
US
Elan Corp. PlcElan Corp. Plc
01 Mar 2010
Multiple sclerosis relapsePhase 1
CA
Elan Corp. PlcElan Corp. Plc
01 Mar 2010
Hematologic NeoplasmsPhase 1
US
Elan Corp.Elan Corp.
-
Hematologic NeoplasmsPhase 1-
Perrigo Co. PlcPerrigo Co. Plc
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free